Richard Chin joins board of ImmunoCellular Therapeutics

Adds drug development experience as company looks to advance brain tumour vaccine

Former CEO of the non-profit pharma firm OneWorld Health Dr Richard Chin has joined the board of directors at ImmunoCellular Thereapeutics.

Chin, who currently serves on the adjunct faculty of the University of California, San Francisco School of Medicine, will also become chair of the compensation committee at ImmunoCellular – a US-based clinical-stage company developing immune-based therapies for the treatment of cancer.

“His extensive experience in drug development will be valuable as the company advances its phase II clinical trial of ICT-107,” said ImmunoCellular's chairman Dr John Yu, referencing the company's cancer vaccine currently in development for the brain tumour glioblastoma multiforme.

Chin spent left OneWorld Health in 2011 after spending three years leading the organisation, which aims to develop new treatments for neglected diseases. It is largely funded by the Bill and Melinda Gates Foundation.

Prior to this role, he was president and CEO of biopharma Oxigene from 2006 to 2008 and he has also held senior roles at Elan and Genentech.